Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Travere Therapeutics, Inc. Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial SAN DIEGO, Oct. 17, 2024 (GLOBE NE...